Sinopharm Group Co. Ltd. (SHTDY)
OTCMKTS · Delayed Price · Currency is USD
11.70
+0.03 (0.22%)
Apr 30, 2025, 4:00 PM EDT

Sinopharm Group Statistics

Total Valuation

Sinopharm Group has a market cap or net worth of 7.38 billion. The enterprise value is 18.74 billion.

Market Cap 7.38B
Enterprise Value 18.74B

Important Dates

The last earnings date was Friday, April 25, 2025.

Earnings Date Apr 25, 2025
Ex-Dividend Date Jun 18, 2024

Share Statistics

Current Share Class n/a
Shares Outstanding n/a
Shares Change (YoY) +0.35%
Shares Change (QoQ) -0.66%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 1.34B

Valuation Ratios

The trailing PE ratio is 7.56.

PE Ratio 7.56
Forward PE n/a
PS Ratio 0.09
PB Ratio 0.41
P/TBV Ratio 0.76
P/FCF Ratio 2.29
P/OCF Ratio 2.16
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.81, with an EV/FCF ratio of 5.80.

EV / Earnings 19.19
EV / Sales 0.23
EV / EBITDA 5.81
EV / EBIT 7.21
EV / FCF 5.80

Financial Position

The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.61.

Current Ratio 1.34
Quick Ratio 1.07
Debt / Equity 0.61
Debt / EBITDA 3.56
Debt / FCF 3.37
Interest Coverage 6.65

Financial Efficiency

Return on equity (ROE) is 8.24% and return on invested capital (ROIC) is 5.47%.

Return on Equity (ROE) 8.24%
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) 5.47%
Return on Capital Employed (ROCE) 12.48%
Revenue Per Employee 737,197
Profits Per Employee 9,024
Employee Count 108,217
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -7.37% in the last 52 weeks. The beta is 0.63, so Sinopharm Group's price volatility has been lower than the market average.

Beta (5Y) 0.63
52-Week Price Change -7.37%
50-Day Moving Average 11.98
200-Day Moving Average 12.50
Relative Strength Index (RSI) 51.44
Average Volume (20 Days) 20,894

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Sinopharm Group had revenue of 79.78 billion and earned 976.57 million in profits. Earnings per share was 0.31.

Revenue 79.78B
Gross Profit 6.00B
Operating Income 2.43B
Pretax Income 1.90B
Net Income 976.57M
EBITDA 2.72B
EBIT 2.43B
Earnings Per Share (EPS) 0.31
Full Income Statement

Balance Sheet

The company has 6.25 billion in cash and 10.87 billion in debt, giving a net cash position of -4.62 billion.

Cash & Cash Equivalents 6.25B
Total Debt 10.87B
Net Cash -4.62B
Net Cash Per Share n/a
Equity (Book Value) 17.80B
Book Value Per Share 3.55
Working Capital 13.00B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.41 billion and capital expenditures -181.85 million, giving a free cash flow of 3.23 billion.

Operating Cash Flow 3.41B
Capital Expenditures -181.85M
Free Cash Flow 3.23B
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 7.53%, with operating and profit margins of 3.04% and 1.22%.

Gross Margin 7.53%
Operating Margin 3.04%
Pretax Margin 2.39%
Profit Margin 1.22%
EBITDA Margin 3.41%
EBIT Margin 3.04%
FCF Margin 4.05%

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 4.23%.

Dividend Per Share 0.50
Dividend Yield 4.23%
Dividend Growth (YoY) 7.35%
Years of Dividend Growth 4
Payout Ratio 29.23%
Buyback Yield -0.35%
Shareholder Yield 3.88%
Earnings Yield 13.23%
FCF Yield 43.75%
Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Sinopharm Group has an Altman Z-Score of 2.12. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.12
Piotroski F-Score n/a